FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053881211> ?p ?o ?g. }

• W2053881211 endingPage "627" @default.
• W2053881211 startingPage "613" @default.
• W2053881211 abstract "Objective:Currently, direct comparative evidence or head-to-head data between BG-12 (dimethyl fumarate) and other disease-modifying treatments (DMTs) is limited. This study is a systematic review and data synthesis of published randomized clinical trials comparing the efficacy and safety of existing DMTs to BG-12 for relapsing–remitting multiple sclerosis (RRMS).Methods:A systematic review was conducted by searching MEDLINE, EMBASE, and the Cochrane Library for English-language publications from 1 January 1960 to 15 November 2012. Clinicaltrials.gov, metaRegister of Controlled Trials, and conference proceedings from relevant annual symposia were also hand searched. Two independent reviewers collected and extracted data, with discrepancies reconciled by a third reviewer. Included studies were randomized controlled trials (RCTs) of DMTs (interferon [IFN] beta-1a, IFN beta-1b, glatiramer acetate [GA], BG-12, fingolimod, natalizumab, and teriflunomide) in adults with RRMS. Mixed treatment comparisons were conducted to derive the relative effect size for the included treatments. Annualized relapse rate (ARR), disability progression, and safety outcomes were assessed.Results:BG-12 240 mg twice a day (BID) significantly reduces ARR compared to placebo (rate ratio: 0.529 [95% CI: 0.451–0.620]), IFNs (0.76 [95% CI: 0.639–0.904]), GA (0.795 [95% CI: 0.668–0.947]), and teriflunomide 7 mg and 14 mg (0.769 [95% CI: 0.610–0.970] and 0.775 [95% CI: 0.614–0.979]), and does not show a significant difference when compared to fingolimod. Only natalizumab was significantly superior to BG-12 in reducing ARR. BG-12 also demonstrated favorable results for disability and safety outcomes.Conclusion:Based on indirect comparison, BG-12 offers an effective oral treatment option for patients with RRMS with an overall promising efficacy and safety profile compared to currently approved DMTs. Key limitations of the systematic review were the large heterogeneity in patients enrolled and the variability in the definition of outcomes in included trials." @default.
• W2053881211 created "2016-06-24" @default.
• W2053881211 creator A5007097302 @default.
• W2053881211 creator A5013481282 @default.
• W2053881211 creator A5015357102 @default.
• W2053881211 creator A5029734617 @default.
• W2053881211 creator A5043178404 @default.
• W2053881211 creator A5058311965 @default.
• W2053881211 creator A5066166395 @default.
• W2053881211 creator A5078067575 @default.
• W2053881211 creator A5086756599 @default.
• W2053881211 date "2013-11-26" @default.
• W2053881211 modified "2023-10-16" @default.
• W2053881211 title "Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison" @default.
• W2053881211 cites W1529192025 @default.
• W2053881211 cites W1967838438 @default.
• W2053881211 cites W1973550674 @default.
• W2053881211 cites W1986215651 @default.
• W2053881211 cites W1990918979 @default.
• W2053881211 cites W2005501262 @default.
• W2053881211 cites W2005506388 @default.
• W2053881211 cites W2015238396 @default.
• W2053881211 cites W2043591841 @default.
• W2053881211 cites W2055385861 @default.
• W2053881211 cites W2061005334 @default.
• W2053881211 cites W2063929317 @default.
• W2053881211 cites W2064775943 @default.
• W2053881211 cites W2072295861 @default.
• W2053881211 cites W2092972484 @default.
• W2053881211 cites W2093009907 @default.
• W2053881211 cites W2103758700 @default.
• W2053881211 cites W2104948944 @default.
• W2053881211 cites W2115989506 @default.
• W2053881211 cites W2123700459 @default.
• W2053881211 cites W2139367012 @default.
• W2053881211 cites W2144318111 @default.
• W2053881211 cites W2149021083 @default.
• W2053881211 cites W2151340435 @default.
• W2053881211 cites W2152511465 @default.
• W2053881211 cites W2166394031 @default.
• W2053881211 cites W2166983650 @default.
• W2053881211 cites W2169098250 @default.
• W2053881211 cites W2312240793 @default.
• W2053881211 cites W2321043971 @default.
• W2053881211 cites W2331501350 @default.
• W2053881211 cites W4211254511 @default.
• W2053881211 cites W4234254101 @default.
• W2053881211 doi "https://doi.org/10.1185/03007995.2013.863755" @default.
• W2053881211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24195574" @default.
• W2053881211 hasPublicationYear "2013" @default.
• W2053881211 type Work @default.
• W2053881211 sameAs 2053881211 @default.
• W2053881211 citedByCount "71" @default.
• W2053881211 countsByYear W20538812112014 @default.
• W2053881211 countsByYear W20538812112015 @default.
• W2053881211 countsByYear W20538812112016 @default.
• W2053881211 countsByYear W20538812112017 @default.
• W2053881211 countsByYear W20538812112018 @default.
• W2053881211 countsByYear W20538812112019 @default.
• W2053881211 countsByYear W20538812112020 @default.
• W2053881211 countsByYear W20538812112021 @default.
• W2053881211 countsByYear W20538812112022 @default.
• W2053881211 countsByYear W20538812112023 @default.
• W2053881211 crossrefType "journal-article" @default.
• W2053881211 hasAuthorship W2053881211A5007097302 @default.
• W2053881211 hasAuthorship W2053881211A5013481282 @default.
• W2053881211 hasAuthorship W2053881211A5015357102 @default.
• W2053881211 hasAuthorship W2053881211A5029734617 @default.
• W2053881211 hasAuthorship W2053881211A5043178404 @default.
• W2053881211 hasAuthorship W2053881211A5058311965 @default.
• W2053881211 hasAuthorship W2053881211A5066166395 @default.
• W2053881211 hasAuthorship W2053881211A5078067575 @default.
• W2053881211 hasAuthorship W2053881211A5086756599 @default.
• W2053881211 hasConcept C126322002 @default.
• W2053881211 hasConcept C142724271 @default.
• W2053881211 hasConcept C168563851 @default.
• W2053881211 hasConcept C1862650 @default.
• W2053881211 hasConcept C197934379 @default.
• W2053881211 hasConcept C203014093 @default.
• W2053881211 hasConcept C204787440 @default.
• W2053881211 hasConcept C27081682 @default.
• W2053881211 hasConcept C2776036978 @default.
• W2053881211 hasConcept C2776478404 @default.
• W2053881211 hasConcept C2776819417 @default.
• W2053881211 hasConcept C2777703276 @default.
• W2053881211 hasConcept C2778577042 @default.
• W2053881211 hasConcept C2778715236 @default.
• W2053881211 hasConcept C2779134260 @default.
• W2053881211 hasConcept C2780640218 @default.
• W2053881211 hasConcept C2781004633 @default.
• W2053881211 hasConcept C2910384678 @default.
• W2053881211 hasConcept C44249647 @default.
• W2053881211 hasConcept C512399662 @default.
• W2053881211 hasConcept C71924100 @default.
• W2053881211 hasConcept C82789193 @default.
• W2053881211 hasConceptScore W2053881211C126322002 @default.
• W2053881211 hasConceptScore W2053881211C142724271 @default.
• W2053881211 hasConceptScore W2053881211C168563851 @default.

• next